Table 2. Parameter values used in simulation model.

Model parameter (unit)	Values used in individual simulations
Infection rate (per day)	5.56 × 10 − 8, 1.67 × 10 − 8, 6.02 × 10 − 8, 2.28 × 10 − 7, 2.29 × 10 − 7
Recovery rate f (inverse of duration of natural infection) (per day)	1/84, 1/160, 1/185, 1/240, 1/365
Treatment rate γ (inverse of time in days until patients first seek treatment) (per day)	1/3, 1/12, 1/13, 1/52
Cure rate for gepotidacin treatment, assuming double dose (inverse of treatment duration, i.e. time over MIC) (per day)	1.778 ( = 1/13.5h)
Cure rate for ciprofloxacin treatment, assuming single dose (inverse of treatment duration) (per day)	6 ( = 1/4h)
Proportion of patients that return for second round treatment p	1, 0.8, 0.6, 0.5
Mutation rate without treatment σb (substitutions per nt per day)	3.12 × 10 − 9, 2.45 × 10 − 8
Mutation rate with treatment σt (substitutions per nt per day)	3.12 × 10 − 9, 2.45 × 10 − 8, 4.9 × 10 − 8, 1.23 × 10 − 7, 2.45 × 10 − 7, 2.45 × 10 − 6, 2.45 × 10 − 5, 7.95 × 10 − 5, 9.66 × 10 − 4
Point-of-care test usage (%)	0, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100
Total simulated population	1.5 × 106
Initial number of infected individuals/equilibrium incidence rate	22,000
Initial prevalence of parC D86N (%)	0, 0.06, 0.18, 0.462, 0.669, 1.5, 2, 2.9, 3, 5.9, 6.5, 8.6, 13, 19.3, 38.6
Initial prevalence of gyrA A92T (%)	0, 1
Initial prevalence of double mutant (parC D86N/gyrA A92T) (%)	0

MIC: minimum inhibitory concentration.

All rates are per day. If more than one value is given, the whole range of values has been tested in different simulations. See Supplementary Material 2 for parameter combinations used in individual simulations. References and the basis of assumptions are included in the Supplementary Material 1, Supplementary Table 2.